Shares of Autolus Therapeutics plc (NASDAQ:AUTL – Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $2.16, but opened at $2.24. Autolus Therapeutics shares last traded at $2.27, with a volume of 119,994 shares.
Analyst Ratings Changes
A number of brokerages have recently issued reports on AUTL. Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a research note on Friday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a report on Monday, January 13th. Finally, The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the company from $7.00 to $7.60 in a report on Monday, November 18th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $10.40.
Check Out Our Latest Analysis on Autolus Therapeutics
Autolus Therapeutics Stock Up 3.5 %
Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period last year, the company earned ($0.26) earnings per share. On average, equities analysts expect that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.
Hedge Funds Weigh In On Autolus Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of AUTL. Dumont & Blake Investment Advisors LLC acquired a new stake in shares of Autolus Therapeutics in the 4th quarter worth about $35,000. ProShare Advisors LLC acquired a new position in Autolus Therapeutics during the 2nd quarter valued at about $43,000. Arkadios Wealth Advisors bought a new position in Autolus Therapeutics in the 4th quarter worth about $47,000. Capstone Investment Advisors LLC acquired a new stake in shares of Autolus Therapeutics in the third quarter valued at approximately $51,000. Finally, Avanza Fonder AB bought a new stake in shares of Autolus Therapeutics during the fourth quarter valued at approximately $75,000. Institutional investors and hedge funds own 72.83% of the company’s stock.
Autolus Therapeutics Company Profile
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Further Reading
- Five stocks we like better than Autolus Therapeutics
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
- How Investors Can Find the Best Cheap Dividend Stocks
- MarketBeat Week in Review – 01/20 – 01/24
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Netflix Stock Positioned for Explosive Growth in 2025
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.